Could 2025 Oncology Have Saved Steve Jobs from Pancreatic Cancer? A Deep Dive into Past and Future Treatments February 21,…
Browsing: Pancreatic
… Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr.…
Pancreatic Cancer Updates – Insights from Vincent Chung, MDDiscover the latest advancements in the field of pancreatic cancer through an…
Michael Chuong, MD, from Baptist Health has conducted a Phase 2 trial on the use of ablative MRI-guided stereotactic body…
This is a deep dive into the groundbreaking NAPOLI-3 Trial, a study that has generated significant interest and discussion in…
Dr. Monica Niger, from Fondazione IRCCS Istituto Nazionale Tumori, provided a summary of the NALIRIFOX vs FOLFIRINOX vs gemcitabine plus…
Focal Adhesion Kinase: Can Adding Fibroblasts and C-X-C Chemokine Help With Suppression? Arsen Osipov MD By Arsen Osipov, MD In…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and nab-paclitaxel…
Open Label Phase III TIGeR-PaC Interim Data Observes 6-Month Median Survival Benefit: RenovoGem (Intra-Arterial Gemcitabine) Versus IV Gemcitabine and Nab-paclitaxel…
Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By…
iFrame is not supported! Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally…
Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By…
This study that we presented at ASCO is titled a descriptive study on the treatment and outcomes of patients with…
Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In…
Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In…
Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and…
Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and…
Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about…
Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about…
John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he…
John Strickler, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute at Duke University. In this video, he…
Charles Lopez, MD, Ph.D., Associate Professor of Medicine, School of Medicine Cell and Developmental Biology Graduate Program, School of Medicine,…
Charles Lopez, MD, Ph.D., Associate Professor of Medicine, School of Medicine Cell and Developmental Biology Graduate Program, School of Medicine,…
Vincent J. Picozzi Jr, MD, Hematologist/Oncologist from Virginia Mason Medical Center. In this interview, he speaks about the ASCO GI…
Vincent J. Picozzi Jr, MD, Hematologist/Oncologist from Virginia Mason Medical Center. In this interview, he speaks about the ASCO GI…
Diana Hanna, MD is the Program Director over Hoag’s Phase 1 Cancer Research within the Hoag Family Cancer Institute. Dr.…
Diana Hanna, MD is the Program Director over Hoag’s Phase 1 Cancer Research within the Hoag Family Cancer Institute. Dr.…
Heloisa Soares, MD, Ph.D., Associate Professor at Huntsman Cancer Institute. In this video, she speaks about the ASCO GI 2022…
Heloisa Soares, MD, Ph.D., Associate Professor at Huntsman Cancer Institute. In this video, she speaks about the ASCO GI 2022…
Srinivas Gaddam, MD, Interventional Gastroenterologist, Assistant professor of Medicine at Cedars-Sinai Cancer speaks about Study: Incidence of Pancreatic Cancer Rising…
Srinivas Gaddam, MD, Interventional Gastroenterologist, Assistant professor of Medicine at Cedars-Sinai Cancer speaks about Study: Incidence of Pancreatic Cancer Rising…
Prof. Hemant Kocher, MBBS, MS, MD, FRCS from the Queen Mary University of London speaks about Pentraxin 3 is a…
Sarah E. Hoffe, MD from H. Lee Moffitt Cancer Center & Research Institute speaks about ASCO Abstract – GRECO-2: A…
Prof. Hemant Kocher, MBBS, MS, MD, FRCS from the Queen Mary University of London speaks about Pentraxin 3 is a…
Sarah E. Hoffe, MD from H. Lee Moffitt Cancer Center & Research Institute speaks about ASCO Abstract – GRECO-2: A…
Ajay Goel, Ph.D., AGAF, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at the City of Hope speaks…
Russell Langan, M.D., Chief of Surgical Oncology and Hepatopancreatobiliary Surgery at Saint Barnabas Medical Center, an RWJBarnabas Health facility, and…
An international team of researchers led by scientists from the University of California San Diego School of Medicine and Moores…
Flavio G. Rocha, MD, FACS, FSSO from the Division of Surgical Oncology, Knight Cancer Institute, Oregon Health and Science University,…
Jason M. Link, Ph.D., Department of Molecular and Medical Genetics, Brenden-Colson Center for Pancreatic Care, Oregon Health and Science University…
Tammy Lo, NP from Norwalk Hospital speaks about Pancreatic Cancer and Reacts to Alex Trebek’s Death from the Disease.Pancreatic CancerCancer…
Apurna Jegannathen, MD from University Hospital Of North Midlands discusses the abstract A Sustained Response of Maintenance Therapy in Pancreatic…
Shahid Gilani, MD Certified Oncologist and Radiation oncologists from the University Hospital Of North Midlands discusses the study A Sustained…
Professor Alessandro Zerbi of the Humanitas Research Hospital Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy (PALN). Summary Brief: The only curative…
Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial…
Siqing Fu, M.D., Ph.D. MD Anderson Cancer Center discusses Soricimed Announces Resumption of MD Anderson’s Investigator-Initiated Phase 1b Clinical Trial…
Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type…
Philadelphia, PA (June 8, 2020) –  Oncoceutics announced today a Brown University award of $3.4 million that will be used…
Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed answers if the phase I study of defactinib combined…
Andrea Wang-Gillam, MD, PhD of Washington University School of Medicine @WUSTLmed discusses the phase I study of defactinib combined with…
Earn CME: https://www.naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://www.naccme.com/program/19-gdu… In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Earn CME: https://naccme.com/program/19-gdugi-3 In this webcast from the ‘Chemotherapeutic Advances in the Treatment of Pancreatic Adenocarcinoma: Improving Outcomes and Treatment…
Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to…
GRACE is very excited to bring to you more videos from our program, Supportive Care in Cancer Treatment.Arjun Gupta, MD…
Source: https://www.spreaker.com/user/cancergrace/supportive-care-6-pert Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video,…
World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of…
– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric…
Finding May Explain Why Promising Drugs Work – And When They Won’t   CHARLOTTESVILLE, Va., Sept. 26, 2019 – A…
TORONTO, CANADA / ACCESSWIRE / September 24, 2019 / Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today…
Shauna Campbell, MD of Cleveland Clinic shares three nomograms that were presented on salvage radiotherapy. _____ The integration of prostate-specific…
Shauna Campbell, MD of Cleveland Clinic answers a question received from colleagues: how does it differ from previously published nomograms?…
New discovery opens new potentially effective approaches to utilize checkpoint inhibitors for treatment of pancreatic cancer and other types of…
Afsaneh Barzi, MD of Norris Cancer Center provides insight on the still unanswered questions in the POLO study.
Afsaneh Barzi, MD of Norris Cancer Center explains the phase III POLO trial, a maintenance treatment following first-line platinum-based chemotherapy…
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late…
Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6…
Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 potentially shows promise in ovarian, metastatic prostate and pancreatic cancer.
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center shares the important role biomarkers have in the treatment of pancreatic…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center describes the outcomes from the POLO study in pancreatic cancer and…
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center explains the potential of the POLO trial maintenance with olaparib in…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope discusses details from APACT study, a phase…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope shares statistics and data on strategies that…
Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope provides outcomes on the POLO Trial with…
Thomas A. Abrams, Senior Physician and Assistant Medical Professor at Harvard Medical School provides results about the APACT Study. APACT…
Dr. Thomas A. Abrams, Senior Physician and Assistant Professor of Medicine at Harvard Medical School discusses whether the POLO Trial…
Michael Hall, MD Of Fox Chase Cancer Center Discusses POLO Trial: PFS Increased With Olaparib As Maintenance Therapy For BRCA+…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Personalized Medicine In Pancreas Cancer. At MOASC…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Know Your Tumor Initiative. At MOASC Oncology…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Evolution Of Pancreatic Cancer Treatment. At MOASC…
Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Elaborating On Pancreas Cancer. At MOASC Oncology…
Andrew Hendifar, M.D. Medical Director, Pancreatic Cancer Cedars-Sinai Medical Center, Discusses Personalized Therapy For Pancreas Cancer: Have We Arrived? Dr.…
John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses Comprehensive Genomic Profiling Of Pancreatic Cancer. At The…
Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of…
Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of…
Zev Wainberg, M.D. Co-Director UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Hematology Oncology David Geffen School Of Medicine At…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann…
Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer…
Yung Lyou, MD, UC Irvine Health, talks about Keynote 61 Trial | See if Pembrolizumab Can be Moved to the…
Yung Lyou, MD, UC Irvine Health, talks about Weighing Judgment Before Giving Ramucirumab | Ramucirumab is Viable Choice After REACH-2…
Yung Lyou, MD, UC Irvine Health, talks about Selecting Patients for Adjuvant Pancreatic Treatment | Determine Who Has Better Performance…
Yung Lyou, MD, UC Irvine Health, talks PRODIGE 24 Showed FOLFIRINOX has Benefits | FOLFIRINOX was Compared to Single-Agent Gemcitabine…
Richard Goldberg, MD, on preoperative chemotherapy in pancreatic cancer and whether the PREOPANC-1 has influenced the path of treatment
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the Agreement of a Single IRB Review | Single IRG Approval…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, shares how the Study Brought Together Six Academic Centers | BMS, Apexigen,…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains how No One Else is Focusing on Pancreatic Cancer | Answer…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Focuses on Frontline Metastatic Pancreatic Cancer | Patients…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Follows Patients for a Period of Time in…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about Lead Investigator of Study, Dr. Vonderheide | Develop New Agents…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the combination of Gemcitabine + Abraxane – Standard for Pancreatic Cancer…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about the Trial Combining Immunotherapy & Chemotherapy | Survival will be…
John Leighton, MD, explains shares the results of the PREOPANC-1 study and, resectable pancreatic cancer patients should recieve preoperative chemotherapy…
Al Benson III, MD, FACP, Professor of Medicine, Northwestern University, shares the outcomes of the ECOG-ACRIN study in advanced pancreatic…
In this interview, Jeff Evans, PhD, from the University of Glasgow, Glasgow, UK, provides an update on the current landscape…
Jon Eckard, PhD, TYME Inc., explains Not Much Getting Approval for Pancreatic Cancer | Cost of cancer care is very…
Jon Eckard, PhD, TYME Inc., explains Taking Advantage of the Metabolism of a Cancer Delivering drug specifically to the cancer…
Jon Eckard, PhD, TYME Inc., explains Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing at Annual Meeting…